PE20090159A1 - COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs - Google Patents
COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARsInfo
- Publication number
- PE20090159A1 PE20090159A1 PE2008000425A PE2008000425A PE20090159A1 PE 20090159 A1 PE20090159 A1 PE 20090159A1 PE 2008000425 A PE2008000425 A PE 2008000425A PE 2008000425 A PE2008000425 A PE 2008000425A PE 20090159 A1 PE20090159 A1 PE 20090159A1
- Authority
- PE
- Peru
- Prior art keywords
- indol
- chloro
- fluorine
- alkyl
- propionic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
Abstract
REFERIDA A UN DERIVADO DE ACIDO INDOL-PROPIONICO DE FORMULA (I), DONDE X2 Y X3 SON CH O N; UNO DE X1 Y X4 ES N O CR4 Y EL OTRO DE X1 Y X4 ES N O CH; Ar ES ARILO O HETEROARILO; R1 ES C(O)OR8, C(O)NR9R10, ENTRE OTROS; R2 Y R3 SON H O JUNTOS FORMAN UN CICLOALQUILO MONOCICLICO DE 3 A 7 MIEMBROS; R4 ES H, FLUOR, METOXI, METOXI SUSTITUIDO CON FLUOR, CLORO; R5 ES FLUOR, CLORO, ALQUILO C1-C3, ENTRE OTROS; R6 ES H, FLUOR, CLORO, ALQUILO C1-C3, ENTRE OTROS; R7 ES HALOGENO, CN, NO2, ALQUILO, ENTRE OTROS; R8 ES H, FENILO, HETEROARILO MONOCICLICO DE 5 A 7 MIEMBROS, ENTRE OTROS; R9 Y R10 SON H, FENILO, ALQUILO, HETEROARILO MONOCICLICO DE 5 A 7 MIEMBROS, ENTRE OTROS; m ES UN ENTERO DE 0 A 5. SON COMPUESTOS PREFERIDOS: ACIDO 3-[5-CLORO-1-(4'-TRIFLUOROMETIL-BIFENIL-3-SULFONIL)-1H-INDOL-3-IL]-PROPIONICO, ACIDO 3-[5-CLORO-1-(3'-CLORO-BIFENIL-3-SULFONIL)-1H-INDOL-3-IL]-PROPIONICO, ACIDO 3-[5-CLORO-1-(4'-METOXI-BIFENIL-3-SULFONIL)-1H-INDOL-3-IL]-PROPIONICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES ACTIVADOS DEL PROLIFERADOR DE PEROXISOMA (PPARs) Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS DEL PESO, TRANSTORNOS POR LIPIDOS, TRANSTORNOS METABOLICOS, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89387107P | 2007-03-08 | 2007-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090159A1 true PE20090159A1 (es) | 2009-02-21 |
Family
ID=39590187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000425A PE20090159A1 (es) | 2007-03-08 | 2008-03-04 | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
Country Status (16)
Country | Link |
---|---|
US (2) | US8053463B2 (es) |
EP (1) | EP2114879A1 (es) |
JP (1) | JP2010520877A (es) |
KR (1) | KR20090118055A (es) |
CN (1) | CN101679250A (es) |
AR (1) | AR065633A1 (es) |
AU (1) | AU2008222810A1 (es) |
BR (1) | BRPI0808440A2 (es) |
CA (1) | CA2679411A1 (es) |
CL (1) | CL2008000690A1 (es) |
IL (1) | IL200548A0 (es) |
MX (1) | MX2009009292A (es) |
PE (1) | PE20090159A1 (es) |
RU (1) | RU2009137124A (es) |
TW (1) | TW200845980A (es) |
WO (1) | WO2008109700A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8673928B2 (en) | 2009-11-18 | 2014-03-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112012015745A2 (pt) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
EP2672967B1 (en) | 2011-02-07 | 2018-10-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2709622A4 (en) | 2011-05-17 | 2015-03-04 | Plexxikon Inc | CINEMA MODULATION AND INDICATIONS THEREFOR |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
WO2013187696A1 (ko) * | 2012-06-12 | 2013-12-19 | 동국대학교 산학협력단 | C형 간염 바이러스의 게놈 복제의 선택적 저해 활성을 갖는 인돌계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 c형 간염의 예방 또는 치료용 약학적 조성물 |
CN104981247A (zh) | 2012-09-06 | 2015-10-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
CN104903494B (zh) * | 2012-09-21 | 2017-11-03 | 瑞奥可塞恩探索集团有限公司 | 用于电解液体的电池 |
PE20151280A1 (es) | 2012-12-21 | 2015-09-12 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
EP2970265B1 (en) | 2013-03-15 | 2018-08-08 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
SG11201509338QA (en) | 2013-05-30 | 2015-12-30 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112018005497A2 (pt) | 2015-09-21 | 2018-10-09 | Plexxikon Inc | compostos heterocíclicos e usos dos mesmos |
RU2018123825A (ru) | 2015-12-07 | 2020-01-15 | Плексксикон Инк. | Соединения и способы для модуляции киназ, и показания для этого |
ES2904615T3 (es) | 2016-03-16 | 2022-04-05 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones al respecto |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
EP3558991A2 (en) | 2016-12-23 | 2019-10-30 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
JP2020511467A (ja) | 2017-03-20 | 2020-04-16 | プレキシコン インコーポレーテッドPlexxikon Inc. | ブロモドメインを阻害する4−(1−(1,1−ジ(ピリジン−2−イル)エチル)−6−(3,5−ジメチルイソオキサゾール−4−イル)−1H−ピロロ[3,2−b]ピリジン−3−イル)安息香酸の結晶形 |
WO2018205016A1 (en) * | 2017-05-08 | 2018-11-15 | The Governors Of The University Of Alberta | Peroxisome biomarkers in hiv disease progression and peroxisome activating drugs for hiv treatment |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
JP7170030B2 (ja) | 2017-07-25 | 2022-11-11 | プレキシコン インコーポレーテッド | キナーゼを調節する化合物の製剤 |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
EP3700574A1 (en) | 2017-10-27 | 2020-09-02 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10321657B1 (en) * | 2018-02-28 | 2019-06-18 | Seminis Vegetable Seeds, Inc. | Pepper hybrid DRPB1707 and parents thereof |
EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1482844A (fr) | 1964-12-31 | 1967-06-02 | Merck & Co Inc | Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs |
US3489767A (en) | 1966-01-12 | 1970-01-13 | Sumitomo Chemical Co | 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives |
US3511841A (en) | 1967-05-29 | 1970-05-12 | Sterling Drug Inc | 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines |
US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
FR2009259A1 (es) | 1968-05-24 | 1970-01-30 | Acraf | |
GB1573212A (en) | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
DE3246932A1 (de) | 1982-12-16 | 1984-06-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | Substituierte 5h-pyrimido(5,4-b)indole |
US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
EP0154734B1 (en) | 1984-03-15 | 1990-08-29 | Immunex Corporation | Immediate ligand detection assay, a test kit and its formation |
US5688655A (en) | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
GB9004301D0 (en) | 1990-02-26 | 1990-04-18 | Fujisawa Pharmaceutical Co | Indolebutyric acid derivatives and process for preparation thereof |
US5075313A (en) | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
GB9115951D0 (en) | 1991-07-24 | 1991-09-11 | Pfizer Ltd | Indoles |
EP0610793A1 (en) | 1993-02-08 | 1994-08-17 | Takeda Chemical Industries, Ltd. | Tetracyclic morpholine derivatives and their use or analgesics |
IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
PT705279E (pt) | 1993-05-27 | 2003-07-31 | Selectide Corp | Bibliotecas em fase solida codificadas, segregadas topologicamente |
US5840485A (en) | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
US5760040A (en) | 1994-03-30 | 1998-06-02 | Zeria Pharmaceutical Co., Ltd. | Indole derivative for treating overproduction of dihydrotestosterone |
US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
GB9416467D0 (en) | 1994-08-13 | 1994-10-05 | Wellcome Found | Compounds for use in medicine |
US5747276A (en) | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
AU6443498A (en) | 1997-03-07 | 1998-09-22 | Tropix, Inc. | Protease inhibtor assay |
US6178384B1 (en) | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
PL195682B1 (pl) | 1997-12-24 | 2007-10-31 | Sanofi Aventis Deutschland | Pochodne indolu, sposób ich wytwarzania, środek farmaceutyczny oraz zastosowanie pochodnych indolu |
WO1999042102A1 (en) | 1998-02-23 | 1999-08-26 | South Alabama Medical Science Foundation | Indole-3-propionic acids, salts and esters thereof used as medicaments |
CA2327695A1 (en) | 1998-04-08 | 1999-10-21 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
DE19821002A1 (de) | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
EP1085846A2 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
DE60027420T2 (de) | 1999-04-28 | 2006-11-16 | Aventis Pharma Deutschland Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
DK1177187T3 (da) | 1999-04-28 | 2007-10-15 | Sanofi Aventis Deutschland | Diarylsyrederivater som PPAR-receptorligander |
ATE316071T1 (de) | 1999-09-17 | 2006-02-15 | Kyorin Seiyaku Kk | O-anisamid-derivate |
FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
ATE407919T1 (de) | 2000-05-29 | 2008-09-15 | Kyorin Seiyaku Kk | Substituierte phenylpropionsäure-derivate |
US6608059B1 (en) | 2000-06-27 | 2003-08-19 | Smithkline Beecham Corporation | Fatty acid synthase inhibitors |
MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
MXPA03011558A (es) | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
EP1267111A1 (en) | 2001-06-15 | 2002-12-18 | Dsm N.V. | Pressurized fluid conduit |
WO2003024395A2 (en) | 2001-09-14 | 2003-03-27 | Tularik Inc. | Linked biaryl compounds |
PT1501826E (pt) | 2002-02-01 | 2007-01-31 | Hoffmann La Roche | Idoles substituídos como agonistas de receptores alfa-1 |
AU2003208711A1 (en) * | 2002-02-12 | 2003-09-04 | Akzo Nobel N.V. | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders |
EP1480642B1 (en) | 2002-02-25 | 2008-11-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
US6806265B2 (en) | 2002-05-16 | 2004-10-19 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
US20050256117A1 (en) | 2002-06-14 | 2005-11-17 | Meng Hsin Chen | Ophthalmic compositions for treating ocular hypertension |
DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
WO2004007439A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | ビアリール誘導体 |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
AU2003265681A1 (en) | 2002-08-29 | 2004-03-19 | Merck And Co., Inc. | Indoles having anti-diabetic activity |
ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
WO2004056740A1 (en) | 2002-12-20 | 2004-07-08 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
CA2510516A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
RU2356889C2 (ru) | 2003-07-17 | 2009-05-27 | Плекссикон, Инк. | Соединения, являющиеся активными по отношению к рецепторам, активируемым пролифератором пероксисом |
US20100267778A1 (en) | 2003-08-04 | 2010-10-21 | Shinya Kusuda | Diphenyl ether compound, process for producing the same, and use |
US7608639B2 (en) | 2003-10-14 | 2009-10-27 | Eli Lilly And Company | Phenoxyether derivatives as PPAR modulators |
WO2005040114A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
DE602004011985T2 (de) | 2003-11-25 | 2009-03-05 | Eli Lilly And Co., Indianapolis | Modulatoren des peroxisomproliferatoraktivierten rezeptors |
RU2240793C1 (ru) | 2003-12-02 | 2004-11-27 | Лимонов Виктор Львович | Противоопухолевое средство |
CN1886133B (zh) | 2003-12-04 | 2010-12-01 | 财团法人卫生研究院 | 吲哚化合物 |
WO2005060958A1 (en) | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
WO2005092131A1 (en) | 2004-03-01 | 2005-10-06 | Mirko Uzelac | Bipartite butcher's handshalter with couple |
GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
CA2621474A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1,3-disubstituted indole derivatives for use as ppar modulators |
JP2009509932A (ja) * | 2005-09-07 | 2009-03-12 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
-
2008
- 2008-03-04 PE PE2008000425A patent/PE20090159A1/es not_active Application Discontinuation
- 2008-03-05 US US12/043,069 patent/US8053463B2/en active Active
- 2008-03-05 CN CN200880013794A patent/CN101679250A/zh active Pending
- 2008-03-05 MX MX2009009292A patent/MX2009009292A/es not_active Application Discontinuation
- 2008-03-05 BR BRPI0808440-8A patent/BRPI0808440A2/pt not_active IP Right Cessation
- 2008-03-05 KR KR1020097018693A patent/KR20090118055A/ko not_active Application Discontinuation
- 2008-03-05 WO PCT/US2008/055955 patent/WO2008109700A1/en active Application Filing
- 2008-03-05 RU RU2009137124/04A patent/RU2009137124A/ru not_active Application Discontinuation
- 2008-03-05 EP EP08731467A patent/EP2114879A1/en not_active Withdrawn
- 2008-03-05 CA CA002679411A patent/CA2679411A1/en not_active Abandoned
- 2008-03-05 JP JP2009552869A patent/JP2010520877A/ja active Pending
- 2008-03-05 AU AU2008222810A patent/AU2008222810A1/en not_active Abandoned
- 2008-03-07 CL CL200800690A patent/CL2008000690A1/es unknown
- 2008-03-07 TW TW097108189A patent/TW200845980A/zh unknown
- 2008-03-07 AR ARP080100941A patent/AR065633A1/es not_active Application Discontinuation
-
2009
- 2009-08-23 IL IL200548A patent/IL200548A0/en unknown
-
2011
- 2011-09-23 US US13/243,703 patent/US20120015966A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2009137124A (ru) | 2011-04-20 |
US20080255201A1 (en) | 2008-10-16 |
CL2008000690A1 (es) | 2008-09-12 |
EP2114879A1 (en) | 2009-11-11 |
CN101679250A (zh) | 2010-03-24 |
CA2679411A1 (en) | 2008-09-12 |
BRPI0808440A2 (pt) | 2014-07-29 |
TW200845980A (en) | 2008-12-01 |
KR20090118055A (ko) | 2009-11-17 |
MX2009009292A (es) | 2009-09-10 |
US8053463B2 (en) | 2011-11-08 |
AU2008222810A1 (en) | 2008-09-12 |
WO2008109700A1 (en) | 2008-09-12 |
US20120015966A1 (en) | 2012-01-19 |
JP2010520877A (ja) | 2010-06-17 |
AR065633A1 (es) | 2009-06-17 |
IL200548A0 (en) | 2010-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090159A1 (es) | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs | |
CY1118973T1 (el) | Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων | |
CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
PE20191304A1 (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador | |
CY1122610T1 (el) | Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης | |
AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
AR082509A1 (es) | Derivados de imidazopiridina, composiciones farmaceuticas y usos | |
PE20081505A1 (es) | Inhibidores de serina palmitoiltransferasa | |
PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
PE20110368A1 (es) | Moduladores de mif | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
CY1117085T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
PE20120374A1 (es) | Fenilureas y fenilamidas como ligandos del receptor de vanilloides | |
AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
PE20070097A1 (es) | Agonistas del receptor de niacina y composiciones que contienen tales compuestos | |
CY1122744T1 (el) | Ενωσεις τετρακυκλινης | |
PE20050435A1 (es) | Derivados de fenil-piperazina como moduladores de receptores muscarinicos | |
PE20081700A1 (es) | Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |